Alexion Pharmaceuticals Inc.

NASDAQ:ALXN  
181.66
-0.33 (-0.18%)
Products

Alexion Announces FDA Approval Of Ultomiris For Children And Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Published: 06/07/2021 18:05 GMT
Alexion Pharmaceuticals Inc. (ALXN) - Alexion Announces FDA Approval of Ultomiris® (ravulizumab-cwvz) for Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (pnh).
Alexion Pharmaceuticals Inc - Plans to Make Ultomiris Available to Pediatric Patients in U.S. Immediately.
Alexion Pharmaceuticals Inc - Regulatory Filing for Ultomiris in Pediatric Patients With Pnh is Under Review in European Union.